WuXi and I-Mab extend partnership to accelerate biologic development

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: Wuxi, Wuxi biologics, I-Mab, Monoclonal antibody, CMC, Biologics, Bispecific antibodies

I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.

Per the extended collaboration, I-Mab, a China-based biotech focusing on biologics for immuno-oncology and auto-immune diseases through its R&D capabilities, will use WuXi’s chemistry, manufacturing, and control (CMC) development platform.

I-Mab will tap Hong Kong-based WuXi’s CMC expertise for at least five of its biologics programs, and commercial manufacturing for one program in its monoclonal antibody (mAb), bispecific antibody, and fusion protein pipelines. 

Through the 3-year partnership, I-Mab expects to see the acceleration of its pipeline’s development in China and abroad. I-Mab’s president Zheru Zhang said in a statement that the company “will be able to expedite our potential first-in-class and best-in-class biologics to the market to satisfy substantial unmet medical needs with high quality and speed.”

WuXi Biologics stated it will use its business strategy of ‘follow-the-molecule’ in this partnership. A spokesperson for WuXi told us that this strategy focuses on following the customers’ demand for its services to advance biologics through development. This enables WuXi’s revenue to ​grow geometrically’ while projects advance through the development cycle, they said

Additionally, WuXi stated that the partnership follows its global dual sourcing plan in which its partner selects the facilities from its global supply network in China, the EU, and the US to “ensure their global supply and eliminate the risks of inter-company technology transfer.”

Related news

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars